Loading…
Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer
Background This study aimed to explore the prognostic value of tumor mutational burden (TMB) combined with smoking status in advanced non‐small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitor therapy (anti PD‐1/PD‐L1 therapy) combined with chemotherapy or anti‐angiogenesis...
Saved in:
| Published in: | Cancer medicine (Malden, MA) MA), 2021-10, Vol.10 (19), p.6610-6617 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c5097-caae0cb50ad7f2432189ff596dcd1107ff8b7383e140d752e74c1629b372043e3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c5097-caae0cb50ad7f2432189ff596dcd1107ff8b7383e140d752e74c1629b372043e3 |
| container_end_page | 6617 |
| container_issue | 19 |
| container_start_page | 6610 |
| container_title | Cancer medicine (Malden, MA) |
| container_volume | 10 |
| creator | Sun, Li‐Yue Cen, Wen‐Jian Tang, Wen‐Ting Long, Ya‐Kang Yang, Xin‐Hua Ji, Xiao‐Meng Yang, Jiao‐Jiao Zhang, Ren‐Jing Wang, Fang Shao, Jian‐Yong Du, Zi‐Ming |
| description | Background
This study aimed to explore the prognostic value of tumor mutational burden (TMB) combined with smoking status in advanced non‐small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitor therapy (anti PD‐1/PD‐L1 therapy) combined with chemotherapy or anti‐angiogenesis therapy.
Methods
We conducted a retrospective analysis of NSCLC patients who underwent next‐generation sequencing test (either 295‐gene panel NGS or 1021‐gene panel NGS) from September 2017 to November 2020. The relationship between TMB and smoking status was investigated. Kaplan–Meier survival analysis was used to compare progression‐free survival (PFS) of the NSCLC patients who received combination immunotherapy grouped by TMB value and smoking status.
Results
We enrolled 323 cases and 388 cases of NSCLC patients in the 295‐gene panel cohort and 1021‐gene panel cohort, respectively. Positive correlation between TMB and smoking status was found in lung adenocarcinoma, but not in lung squamous cell carcinoma. Participants with both high TMB and smoking status who received immune checkpoint therapy combined with chemotherapy or anti‐angiogenesis therapy had longer PFS than other participants (p |
| doi_str_mv | 10.1002/cam4.4197 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ebef9e9e9e66427daaa7042d49c79a65</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_ebef9e9e9e66427daaa7042d49c79a65</doaj_id><sourcerecordid>2568250682</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5097-caae0cb50ad7f2432189ff596dcd1107ff8b7383e140d752e74c1629b372043e3</originalsourceid><addsrcrecordid>eNp1kk9u1DAUhyMEolXpggsgS2xgMa3jOHG8QapG_KlUxAJYWy_2y4ynsT3YCdXsOAJX4GqcBGemVC0SseJYfl8-Pdm_onhe0rOSUnauwfEzXkrxqDhmlNcL0VT88b31UXGa0obmR1DWiPJpcVRx3shcPy5-fXbh2voVSSOMUyI6uM56NOTGjmsyTi5E4qZcs8HDQLopGvQEEgGyjWHlQ7Ipr9BYPWa0z-9Bsf-DWOcmj0SvUV9vg_UjsX5tOzuz4xojbHd5h_jgf__4mRwMA9GYp2HKLWnwGuOz4kkPQ8LT2-9J8fXd2y_LD4urT-8vlxdXC11TKRYaAKnuagpG9IxXrGxl39eyMdqUJRV933aiaissOTWiZii4Lhsmu0rkk6qwOikuD14TYKO20TqIOxXAqv1GiCsFcbR6QIUd9hLn0TScCQMAgnJmuNRCQlNn15uDazt1Do1GP0YYHkgfVrxdq1X4rloua9bSLHh1K4jh24RpVM6m-WTAY5iSYnXTsprmKaMv_0E3YYr5smZKyDpnhDeZen2gdAwpRezvmimpmnOk5hypOUeZfXG_-zvyb2oycH4AbuyAu_-b1PLiI98r_wCpl9bn</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2579500246</pqid></control><display><type>article</type><title>Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer</title><source>Wiley-Blackwell Open Access Collection</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Sun, Li‐Yue ; Cen, Wen‐Jian ; Tang, Wen‐Ting ; Long, Ya‐Kang ; Yang, Xin‐Hua ; Ji, Xiao‐Meng ; Yang, Jiao‐Jiao ; Zhang, Ren‐Jing ; Wang, Fang ; Shao, Jian‐Yong ; Du, Zi‐Ming</creator><creatorcontrib>Sun, Li‐Yue ; Cen, Wen‐Jian ; Tang, Wen‐Ting ; Long, Ya‐Kang ; Yang, Xin‐Hua ; Ji, Xiao‐Meng ; Yang, Jiao‐Jiao ; Zhang, Ren‐Jing ; Wang, Fang ; Shao, Jian‐Yong ; Du, Zi‐Ming</creatorcontrib><description>Background
This study aimed to explore the prognostic value of tumor mutational burden (TMB) combined with smoking status in advanced non‐small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitor therapy (anti PD‐1/PD‐L1 therapy) combined with chemotherapy or anti‐angiogenesis therapy.
Methods
We conducted a retrospective analysis of NSCLC patients who underwent next‐generation sequencing test (either 295‐gene panel NGS or 1021‐gene panel NGS) from September 2017 to November 2020. The relationship between TMB and smoking status was investigated. Kaplan–Meier survival analysis was used to compare progression‐free survival (PFS) of the NSCLC patients who received combination immunotherapy grouped by TMB value and smoking status.
Results
We enrolled 323 cases and 388 cases of NSCLC patients in the 295‐gene panel cohort and 1021‐gene panel cohort, respectively. Positive correlation between TMB and smoking status was found in lung adenocarcinoma, but not in lung squamous cell carcinoma. Participants with both high TMB and smoking status who received immune checkpoint therapy combined with chemotherapy or anti‐angiogenesis therapy had longer PFS than other participants (p < 0.05).
Conclusions
The combination of TMB with smoking status might be a potential predictor for the efficacy of combination immunotherapy in advanced NSCLC.
The tumor mutational burden (TMB) value correlated with smoking status in lung adenocarcinoma patients, but not in lung squamous cell carcinoma patients in both NGS panels. The TMB value combined with smoking status might be used as a potential prognostic indicator for advanced non‐small cell lung cancer patients receiving immune checkpoint inhibitor combination therapy.</description><identifier>ISSN: 2045-7634</identifier><identifier>EISSN: 2045-7634</identifier><identifier>DOI: 10.1002/cam4.4197</identifier><identifier>PMID: 34469045</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>Adenocarcinoma ; Angiogenesis ; Apoptosis ; Biomarkers, Tumor - metabolism ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - physiopathology ; Chemotherapy ; Clinical Cancer Research ; combination therapy ; Female ; High-Throughput Nucleotide Sequencing - methods ; Humans ; immune checkpoint inhibitor ; Immune checkpoint inhibitors ; Immune Checkpoint Inhibitors - pharmacology ; Immune Checkpoint Inhibitors - therapeutic use ; Immunotherapy ; Immunotherapy - methods ; Lung cancer ; Lung carcinoma ; Lung Neoplasms - drug therapy ; Lung Neoplasms - physiopathology ; Male ; Medical prognosis ; Middle Aged ; Mutation ; Non-small cell lung carcinoma ; non‐small cell lung cancer ; PD-L1 protein ; Prognosis ; Retrospective Studies ; Small cell lung carcinoma ; Smoking ; Smoking - adverse effects ; Software ; Squamous cell carcinoma ; Statistical analysis ; tumor mutational burden</subject><ispartof>Cancer medicine (Malden, MA), 2021-10, Vol.10 (19), p.6610-6617</ispartof><rights>2021 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.</rights><rights>2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5097-caae0cb50ad7f2432189ff596dcd1107ff8b7383e140d752e74c1629b372043e3</citedby><cites>FETCH-LOGICAL-c5097-caae0cb50ad7f2432189ff596dcd1107ff8b7383e140d752e74c1629b372043e3</cites><orcidid>0000-0003-1919-0820</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2579500246/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2579500246?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,37013,44590,46052,46476,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34469045$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sun, Li‐Yue</creatorcontrib><creatorcontrib>Cen, Wen‐Jian</creatorcontrib><creatorcontrib>Tang, Wen‐Ting</creatorcontrib><creatorcontrib>Long, Ya‐Kang</creatorcontrib><creatorcontrib>Yang, Xin‐Hua</creatorcontrib><creatorcontrib>Ji, Xiao‐Meng</creatorcontrib><creatorcontrib>Yang, Jiao‐Jiao</creatorcontrib><creatorcontrib>Zhang, Ren‐Jing</creatorcontrib><creatorcontrib>Wang, Fang</creatorcontrib><creatorcontrib>Shao, Jian‐Yong</creatorcontrib><creatorcontrib>Du, Zi‐Ming</creatorcontrib><title>Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer</title><title>Cancer medicine (Malden, MA)</title><addtitle>Cancer Med</addtitle><description>Background
This study aimed to explore the prognostic value of tumor mutational burden (TMB) combined with smoking status in advanced non‐small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitor therapy (anti PD‐1/PD‐L1 therapy) combined with chemotherapy or anti‐angiogenesis therapy.
Methods
We conducted a retrospective analysis of NSCLC patients who underwent next‐generation sequencing test (either 295‐gene panel NGS or 1021‐gene panel NGS) from September 2017 to November 2020. The relationship between TMB and smoking status was investigated. Kaplan–Meier survival analysis was used to compare progression‐free survival (PFS) of the NSCLC patients who received combination immunotherapy grouped by TMB value and smoking status.
Results
We enrolled 323 cases and 388 cases of NSCLC patients in the 295‐gene panel cohort and 1021‐gene panel cohort, respectively. Positive correlation between TMB and smoking status was found in lung adenocarcinoma, but not in lung squamous cell carcinoma. Participants with both high TMB and smoking status who received immune checkpoint therapy combined with chemotherapy or anti‐angiogenesis therapy had longer PFS than other participants (p < 0.05).
Conclusions
The combination of TMB with smoking status might be a potential predictor for the efficacy of combination immunotherapy in advanced NSCLC.
The tumor mutational burden (TMB) value correlated with smoking status in lung adenocarcinoma patients, but not in lung squamous cell carcinoma patients in both NGS panels. The TMB value combined with smoking status might be used as a potential prognostic indicator for advanced non‐small cell lung cancer patients receiving immune checkpoint inhibitor combination therapy.</description><subject>Adenocarcinoma</subject><subject>Angiogenesis</subject><subject>Apoptosis</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - physiopathology</subject><subject>Chemotherapy</subject><subject>Clinical Cancer Research</subject><subject>combination therapy</subject><subject>Female</subject><subject>High-Throughput Nucleotide Sequencing - methods</subject><subject>Humans</subject><subject>immune checkpoint inhibitor</subject><subject>Immune checkpoint inhibitors</subject><subject>Immune Checkpoint Inhibitors - pharmacology</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Lung cancer</subject><subject>Lung carcinoma</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - physiopathology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Non-small cell lung carcinoma</subject><subject>non‐small cell lung cancer</subject><subject>PD-L1 protein</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Small cell lung carcinoma</subject><subject>Smoking</subject><subject>Smoking - adverse effects</subject><subject>Software</subject><subject>Squamous cell carcinoma</subject><subject>Statistical analysis</subject><subject>tumor mutational burden</subject><issn>2045-7634</issn><issn>2045-7634</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kk9u1DAUhyMEolXpggsgS2xgMa3jOHG8QapG_KlUxAJYWy_2y4ynsT3YCdXsOAJX4GqcBGemVC0SseJYfl8-Pdm_onhe0rOSUnauwfEzXkrxqDhmlNcL0VT88b31UXGa0obmR1DWiPJpcVRx3shcPy5-fXbh2voVSSOMUyI6uM56NOTGjmsyTi5E4qZcs8HDQLopGvQEEgGyjWHlQ7Ipr9BYPWa0z-9Bsf-DWOcmj0SvUV9vg_UjsX5tOzuz4xojbHd5h_jgf__4mRwMA9GYp2HKLWnwGuOz4kkPQ8LT2-9J8fXd2y_LD4urT-8vlxdXC11TKRYaAKnuagpG9IxXrGxl39eyMdqUJRV933aiaissOTWiZii4Lhsmu0rkk6qwOikuD14TYKO20TqIOxXAqv1GiCsFcbR6QIUd9hLn0TScCQMAgnJmuNRCQlNn15uDazt1Do1GP0YYHkgfVrxdq1X4rloua9bSLHh1K4jh24RpVM6m-WTAY5iSYnXTsprmKaMv_0E3YYr5smZKyDpnhDeZen2gdAwpRezvmimpmnOk5hypOUeZfXG_-zvyb2oycH4AbuyAu_-b1PLiI98r_wCpl9bn</recordid><startdate>202110</startdate><enddate>202110</enddate><creator>Sun, Li‐Yue</creator><creator>Cen, Wen‐Jian</creator><creator>Tang, Wen‐Ting</creator><creator>Long, Ya‐Kang</creator><creator>Yang, Xin‐Hua</creator><creator>Ji, Xiao‐Meng</creator><creator>Yang, Jiao‐Jiao</creator><creator>Zhang, Ren‐Jing</creator><creator>Wang, Fang</creator><creator>Shao, Jian‐Yong</creator><creator>Du, Zi‐Ming</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1919-0820</orcidid></search><sort><creationdate>202110</creationdate><title>Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer</title><author>Sun, Li‐Yue ; Cen, Wen‐Jian ; Tang, Wen‐Ting ; Long, Ya‐Kang ; Yang, Xin‐Hua ; Ji, Xiao‐Meng ; Yang, Jiao‐Jiao ; Zhang, Ren‐Jing ; Wang, Fang ; Shao, Jian‐Yong ; Du, Zi‐Ming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5097-caae0cb50ad7f2432189ff596dcd1107ff8b7383e140d752e74c1629b372043e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenocarcinoma</topic><topic>Angiogenesis</topic><topic>Apoptosis</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - physiopathology</topic><topic>Chemotherapy</topic><topic>Clinical Cancer Research</topic><topic>combination therapy</topic><topic>Female</topic><topic>High-Throughput Nucleotide Sequencing - methods</topic><topic>Humans</topic><topic>immune checkpoint inhibitor</topic><topic>Immune checkpoint inhibitors</topic><topic>Immune Checkpoint Inhibitors - pharmacology</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Lung cancer</topic><topic>Lung carcinoma</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - physiopathology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Non-small cell lung carcinoma</topic><topic>non‐small cell lung cancer</topic><topic>PD-L1 protein</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Small cell lung carcinoma</topic><topic>Smoking</topic><topic>Smoking - adverse effects</topic><topic>Software</topic><topic>Squamous cell carcinoma</topic><topic>Statistical analysis</topic><topic>tumor mutational burden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sun, Li‐Yue</creatorcontrib><creatorcontrib>Cen, Wen‐Jian</creatorcontrib><creatorcontrib>Tang, Wen‐Ting</creatorcontrib><creatorcontrib>Long, Ya‐Kang</creatorcontrib><creatorcontrib>Yang, Xin‐Hua</creatorcontrib><creatorcontrib>Ji, Xiao‐Meng</creatorcontrib><creatorcontrib>Yang, Jiao‐Jiao</creatorcontrib><creatorcontrib>Zhang, Ren‐Jing</creatorcontrib><creatorcontrib>Wang, Fang</creatorcontrib><creatorcontrib>Shao, Jian‐Yong</creatorcontrib><creatorcontrib>Du, Zi‐Ming</creatorcontrib><collection>Wiley-Blackwell Open Access Collection</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Cancer medicine (Malden, MA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sun, Li‐Yue</au><au>Cen, Wen‐Jian</au><au>Tang, Wen‐Ting</au><au>Long, Ya‐Kang</au><au>Yang, Xin‐Hua</au><au>Ji, Xiao‐Meng</au><au>Yang, Jiao‐Jiao</au><au>Zhang, Ren‐Jing</au><au>Wang, Fang</au><au>Shao, Jian‐Yong</au><au>Du, Zi‐Ming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer</atitle><jtitle>Cancer medicine (Malden, MA)</jtitle><addtitle>Cancer Med</addtitle><date>2021-10</date><risdate>2021</risdate><volume>10</volume><issue>19</issue><spage>6610</spage><epage>6617</epage><pages>6610-6617</pages><issn>2045-7634</issn><eissn>2045-7634</eissn><abstract>Background
This study aimed to explore the prognostic value of tumor mutational burden (TMB) combined with smoking status in advanced non‐small cell lung cancer (NSCLC) patients who received immune checkpoint inhibitor therapy (anti PD‐1/PD‐L1 therapy) combined with chemotherapy or anti‐angiogenesis therapy.
Methods
We conducted a retrospective analysis of NSCLC patients who underwent next‐generation sequencing test (either 295‐gene panel NGS or 1021‐gene panel NGS) from September 2017 to November 2020. The relationship between TMB and smoking status was investigated. Kaplan–Meier survival analysis was used to compare progression‐free survival (PFS) of the NSCLC patients who received combination immunotherapy grouped by TMB value and smoking status.
Results
We enrolled 323 cases and 388 cases of NSCLC patients in the 295‐gene panel cohort and 1021‐gene panel cohort, respectively. Positive correlation between TMB and smoking status was found in lung adenocarcinoma, but not in lung squamous cell carcinoma. Participants with both high TMB and smoking status who received immune checkpoint therapy combined with chemotherapy or anti‐angiogenesis therapy had longer PFS than other participants (p < 0.05).
Conclusions
The combination of TMB with smoking status might be a potential predictor for the efficacy of combination immunotherapy in advanced NSCLC.
The tumor mutational burden (TMB) value correlated with smoking status in lung adenocarcinoma patients, but not in lung squamous cell carcinoma patients in both NGS panels. The TMB value combined with smoking status might be used as a potential prognostic indicator for advanced non‐small cell lung cancer patients receiving immune checkpoint inhibitor combination therapy.</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>34469045</pmid><doi>10.1002/cam4.4197</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-1919-0820</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-7634 |
| ispartof | Cancer medicine (Malden, MA), 2021-10, Vol.10 (19), p.6610-6617 |
| issn | 2045-7634 2045-7634 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_ebef9e9e9e66427daaa7042d49c79a65 |
| source | Wiley-Blackwell Open Access Collection; Publicly Available Content Database; PubMed Central |
| subjects | Adenocarcinoma Angiogenesis Apoptosis Biomarkers, Tumor - metabolism Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - physiopathology Chemotherapy Clinical Cancer Research combination therapy Female High-Throughput Nucleotide Sequencing - methods Humans immune checkpoint inhibitor Immune checkpoint inhibitors Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Immunotherapy Immunotherapy - methods Lung cancer Lung carcinoma Lung Neoplasms - drug therapy Lung Neoplasms - physiopathology Male Medical prognosis Middle Aged Mutation Non-small cell lung carcinoma non‐small cell lung cancer PD-L1 protein Prognosis Retrospective Studies Small cell lung carcinoma Smoking Smoking - adverse effects Software Squamous cell carcinoma Statistical analysis tumor mutational burden |
| title | Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T17%3A51%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Smoking%20status%20combined%20with%20tumor%20mutational%20burden%20as%20a%20prognosis%20predictor%20for%20combination%20immune%20checkpoint%20inhibitor%20therapy%20in%20non%E2%80%90small%20cell%20lung%20cancer&rft.jtitle=Cancer%20medicine%20(Malden,%20MA)&rft.au=Sun,%20Li%E2%80%90Yue&rft.date=2021-10&rft.volume=10&rft.issue=19&rft.spage=6610&rft.epage=6617&rft.pages=6610-6617&rft.issn=2045-7634&rft.eissn=2045-7634&rft_id=info:doi/10.1002/cam4.4197&rft_dat=%3Cproquest_doaj_%3E2568250682%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5097-caae0cb50ad7f2432189ff596dcd1107ff8b7383e140d752e74c1629b372043e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2579500246&rft_id=info:pmid/34469045&rfr_iscdi=true |